Katherine L Nathanson

List of Publications by Year in Descending Order

343 papers	25,504 citations	81 h-index	153 g-index
363 ext. papers	30,522 ext. citations	10.1 avg, IF	6.39 L-index

#	Paper	IF	Citations
343	Evaluation of Classic, Attenuated, and Oligopolyposis of the Colon. *Gastrointestinal Endoscopy Clinics of North America*, **2022**, 32, 95-112	3.3	
342	Abstract OT2-18-01: Harnessing olaparib, palbociclib, and endocrine therapy (HOPE): Phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA1/2-associated, hormone receptor-positive, HER2-negative metastatic breast cancer. *Cancer Research*, **2022**, 82, OT2-18-01-OT2-18-01	10.1	
341	Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants: A Comparative Modeling Analysis.. *JAMA Oncology*, **2022**,	13.4	5
340	Abstract P2-09-01: Population-based risk estimates of clinical subtypes of breast cancer among carriers of germline pathogenic variants in cancer predisposition genes. *Cancer Research*, **2022**, 82, P2-09-01-P2-09-01	10.1	
339	Loss and Promoter Hypermethylation Negatively Predict for Immunogenicity in BRCA-Deficient Ovarian Cancer.. *JCO Precision Oncology*, **2022**, 6, e2100159	3.6	0
338	Performance of polygenic risk scores for cancer prediction in a racially diverse academic biobank.. *Genetics in Medicine*, **2021**,	8.1	2
337	Uptake and outcomes of small intestinal and urinary tract cancer surveillance in Lynch syndrome.. *World Journal of Clinical Oncology*, **2021**, 12, 1023-1036	2.5	
336	Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.. *Genetics in Medicine*, **2021**,	8.1	1
335	Germline Pathogenic Variants in Cancer Predisposition Genes Among Women With Invasive Lobular Carcinoma of the Breast. *Journal of Clinical Oncology*, **2021**, 39, 3918-3926	2.2	6
334	Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry. *Journal of the National Cancer Institute*, **2021**, 113, 1168-1176	9.7	9
333	Discovery and fine-mapping of height loci via high-density imputation of GWASs in individuals of African ancestry. *American Journal of Human Genetics*, **2021**, 108, 564-582	11	7
332	HLA Class I Polymorphisms Influencing Both Peptide Binding and KIR Interactions Are Associated with Remission among Children with Atopic Dermatitis: A Longitudinal Study. *Journal of Immunology*, **2021**, 206, 2038-2044	5.3	3
331	Multigene Panel Testing in Individuals With Hepatocellular Carcinoma Identifies Pathogenic Germline Variants. *JCO Precision Oncology*, **2021**, 5,	3.6	2
330	Evolution of delayed resistance to immunotherapy in a melanoma responder. *Nature Medicine*, **2021**, 27, 985-992	50.5	11
329	Mastermind Like Transcriptional Coactivator 3 (MAML3) Drives Neuroendocrine Tumor Progression. *Molecular Cancer Research*, **2021**, 19, 1476-1485	6.6	3
328	Challenges and Opportunities in Engaging Primary Care Providers in BRCA Testing: Results from the BFOR Study. *Journal of General Internal Medicine*, **2021**, 1	4	2
327	Correlation Between Plasma Catecholamines, Weight, and Diabetes in Pheochromocytoma and Paraganglioma. *Journal of Clinical Endocrinology and Metabolism*, **2021**, 106, e4028-e4038	5.6	6

326	Germline POT1 variants can predispose to myeloid and lymphoid neoplasms. *Leukemia*, **2021**,	10.7	2
325	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
324	Cross-ancestry GWAS meta-analysis identifies six breast cancer loci in African and European ancestry women. *Nature Communications*, **2021**, 12, 4198	17.4	1
323	Identification of 22 susceptibility loci associated with testicular germ cell tumors. *Nature Communications*, **2021**, 12, 4487	17.4	5
322	Risk of Late-Onset Breast Cancer in Genetically Predisposed Women. *Journal of Clinical Oncology*, **2021**, 39, 3430-3440	2.2	3
321	TSLP and IL-7R Variants Are Associated with Persistent Atopic Dermatitis. *Journal of Investigative Dermatology*, **2021**, 141, 446-450.e2	4.3	5
320	Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative. *Genetics in Medicine*, **2021**, 23, 603-605	8.1	5
319	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
318	From Race-Based to Precision Oncology: Leveraging Behavioral Economics and the Electronic Health Record to Advance Health Equity in Cancer Care. *JCO Precision Oncology*, **2021**, 5,	3.6	2
317	A Population-Based Study of Genes Previously Implicated in Breast Cancer. *New England Journal of Medicine*, **2021**, 384, 440-451	59.2	115
316	Clinical Management of Oligopolyposis of Unknown Etiology. *Current Treatment Options in Gastroenterology*, **2021**, 19, 183-197	2.5	1
315	Genetically Inferred Telomere Length and Testicular Germ Cell Tumor Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 1275-1278	4	0
314	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
313	Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. *JAMA Oncology*, **2021**, 7, 1045-1050	13.4	7
312	Genetic risk assessment for hereditary renal cell carcinoma: Clinical consensus statement. *Cancer*, **2021**, 127, 3957-3966	6.4	1
311	EUS-based Pancreatic Cancer Surveillance in Carriers Without a Family History of Pancreatic Cancer. *Cancer Prevention Research*, **2021**, 14, 1033-1040	3.2	0
310	Using a Machine Learning Approach to Identify Low-Frequency and Rare Alleles Associated with Remission of Atopic Dermatitis.. *JID Innovations*, **2021**, 1, 100046		0
309	Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. *Journal of Clinical Oncology*, **2021**, 39, 2564-2573	2.2	12

308	Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in , , or. *Journal of Clinical Oncology*, **2021**, 39, 2497-2505	2.2	34
307	copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. *Cell Reports Medicine*, **2021**, 2, 100394	18	2
306	Targeting PHGDH Upregulation Reduces Glutathione Levels and Resensitizes Resistant NRAS-Mutant Melanoma to MAPK Kinase Inhibition. *Journal of Investigative Dermatology*, **2020**, 140, 2242-2252.e7	4.3	11
305	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
304	Contribution of Germline Predisposition Gene Mutations to Breast Cancer Risk in African American Women. *Journal of the National Cancer Institute*, **2020**, 112, 1213-1221	9.7	25
303	Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG). *Genetics in Medicine*, **2020**, 22, 1142-1148	8.1	35
302	Longitudinal follow-up after telephone disclosure in the randomized COGENT study. *Genetics in Medicine*, **2020**, 22, 1401-1406	8.1	1
301	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
300	Associations of sociodemographic and clinical factors with gastrointestinal cancer risk assessment appointment completion. *Journal of Genetic Counseling*, **2020**, 29, 616-624	2.5	0
299	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nature Communications*, **2020**, 11, 3353	17.4	32
298	Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients. *Clinical Genetics*, **2020**, 97, 601-609	4	3
297	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
296	Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome. *Breast Cancer Research and Treatment*, **2020**, 181, 181-188	4.4	14
295	Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. *European Journal of Cancer*, **2020**, 132, 53-60	7.5	10
294	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
293	Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms. *Blood*, **2020**, 136, 2-4	2.2	
292	Lower abdominal and pelvic radiation and testicular germ cell tumor risk. *PLoS ONE*, **2020**, 15, e0239321	3.7	1
291	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56

290	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. *Journal of Clinical Oncology*, **2020**, 38, 674-685	2.2	133
289	Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. *British Journal of Cancer*, **2020**, 122, 333-339	8.7	60
288	Endoscopic Ultrasound Has Limited Utility in Diagnosis of Gastric Cancer in Carriers of CDH1 Mutations. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 505-508.e1	6.9	12
287	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
286	A Rare Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. *Cancer Research*, **2020**, 80, 3732-3744	10.1	7
285	Lack of pathogenic germline DICER1 variants in males with testicular germ-cell tumors. *Cancer Genetics*, **2020**, 248-249, 49-56	2.3	
284	Tumor detection rates in screening of individuals with SDHx-related hereditary paraganglioma-pheochromocytoma syndrome. *Genetics in Medicine*, **2020**, 22, 2101-2107	8.1	9
283	Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	10
282	Upper Endoscopic Surveillance in Lynch Syndrome Detects Gastric and Duodenal Adenocarcinomas. *Cancer Prevention Research*, **2020**, 13, 1047-1054	3.2	13
281	Association of germline variation with the survival of women with pathogenic variants and breast cancer. *Npj Breast Cancer*, **2020**, 6, 44	7.8	3
280	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. *JCO Precision Oncology*, **2020**, 4,	3.6	2
279	Upper Gastrointestinal Cancer Risk and Surveillance Outcomes in Li-Fraumeni Syndrome. *American Journal of Gastroenterology*, **2020**, 115, 2095-2097	0.7	3
278	Filaggrin sequencing and bioinformatics tools. *Archives of Dermatological Research*, **2020**, 312, 155-158	3.3	6
277	Association between fine mapping thymic stromal lymphopoietin and atopic dermatitis onset and persistence. *Annals of Allergy, Asthma and Immunology*, **2019**, 123, 595-601.e1	3.2	6
276	Hi-Plex2: a simple and robust approach to targeted sequencing-based genetic screening. *BioTechniques*, **2019**, 67, 118-122	2.5	6
275	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
274	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. *JAMA Oncology*, **2019**, 5, 514-522	13.4	23
273	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Human Mutation*, **2019**, 40, 1557-1578	4.7	52

272	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
271	BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. *Human Mutation*, **2019**, 40, 1781-1796	4.7	16
270	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
269	Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer. *Clinical Cancer Research*, **2019**, 25, 4363-4374	12.9	38
268	A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. *Nature Medicine*, **2019**, 25, 454-461	50.5	283
267	Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade. *Cell*, **2019**, 178, 933-948.e14	56.2	141
266	Association of Filaggrin Loss-of-Function Variants With Race in Children With Atopic Dermatitis. *JAMA Dermatology*, **2019**, 155, 1269-1276	5.1	16
265	The role of endoscopy in the management of hereditary diffuse gastric cancer syndrome. *World Journal of Gastroenterology*, **2019**, 25, 2878-2886	5.6	22
264	ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma. *Molecular Cancer Therapeutics*, **2019**, 18, 1637-1648	6.1	7
263	Research participantsQexperiences with return of genetic research results and preferences for web-based alternatives. *Molecular Genetics & Genomic Medicine*, **2019**, 7, e898	2.3	11
262	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
261	Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing. *JCO Precision Oncology*, **2019**, 3,	3.6	9
260	Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multicenter Communication Of GENetic Test Results by Telephone study. *Clinical Genetics*, **2019**, 95, 293-301	4	8
259	Earlier Colorectal Cancer Screening May Be Necessary In Patients With Li-Fraumeni Syndrome. *Gastroenterology*, **2019**, 156, 273-274	13.3	14
258	NRAS Q61R and BRAF G466A mutations in atypical melanocytic lesions newly arising in advanced melanoma patients treated with vemurafenib. *Journal of Cutaneous Pathology*, **2019**, 46, 190-194	1.7	3
257	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
256	Response to Hannah-Shmouni and Stratakis. *Genetics in Medicine*, **2019**, 21, 1256	8.1	
255	Randomized Noninferiority Trial of Telephone vs In-Person Disclosure of Germline Cancer Genetic Test Results. *Journal of the National Cancer Institute*, **2018**, 110, 985-993	9.7	25

254	Clinical germline diagnostic exome sequencing for hereditary cancer: Findings within novel candidate genes are prevalent. *Cancer Genetics*, **2018**, 224-225, 12-20	2.3	4
253	Subphenotype meta-analysis of testicular cancer genome-wide association study data suggests a role for RBFOX family genes in cryptorchidism susceptibility. *Human Reproduction*, **2018**, 33, 967-977	5.7	7
252	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
251	Uncommon Filaggrin Variants Are Associated with Persistent Atopic Dermatitis in African Americans. *Journal of Investigative Dermatology*, **2018**, 138, 1501-1506	4.3	39
250	Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer. *Cancer Immunology Research*, **2018**, 6, 276-287	12.5	46
249	Association of Pancreatic Cancer Susceptibility Variants with Risk of Breast Cancer in Women of European and African Ancestry. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 116-118	4	2
248	Genetic variants demonstrating flip-flop phenomenon and breast cancer risk prediction among women of African ancestry. *Breast Cancer Research and Treatment*, **2018**, 168, 703-712	4.4	22
247	Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genetics in Medicine*, **2018**, 20, 671-682	8.1	74
246	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. *Clinical Cancer Research*, **2018**, 24, 4771-4784	12.9	21
245	Genetic variation in the vitamin D related pathway and breast cancer risk in women of African ancestry in the root consortium. *International Journal of Cancer*, **2018**, 142, 36-43	7.5	7
244	Arginase 2 Suppresses Renal Carcinoma Progression via Biosynthetic Cofactor Pyridoxal Phosphate Depletion and Increased Polyamine Toxicity. *Cell Metabolism*, **2018**, 27, 1263-1280.e6	24.6	45
243	Genetic variation in the Hippo pathway and breast cancer risk in women of African ancestry. *Molecular Carcinogenesis*, **2018**, 57, 1311-1318	5	6
242	Integrated Molecular Characterization of Testicular Germ Cell Tumors. *Cell Reports*, **2018**, 23, 3392-3406	10.6	200
241	Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline or Mutations.. *JCO Precision Oncology*, **2018**, 2, 1-9	3.6	11
240	Returning Individual Genetic Research Results to Research Participants: Uptake and Outcomes Among Patients With Breast Cancer. *JCO Precision Oncology*, **2018**, 2,	3.6	8
239	Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study. *JCO Precision Oncology*, **2018**, 2,	3.6	8
238	CODEX2: full-spectrum copy number variation detection by high-throughput DNA sequencing. *Genome Biology*, **2018**, 19, 202	18.3	34
237	A practical approach to adjusting for population stratification in genome-wide association studies: principal components and propensity scores (PCAPS). *Statistical Applications in Genetics and Molecular Biology*, **2018**, 17,	1.2	11

236	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. *Cancer Cell*, **2017**, 31, 181-193	24.3	350
235	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. *European Journal of Human Genetics*, **2017**, 25, 432-438	5.3	15
234	T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. *Nature*, **2017**, 545, 60-65	50.4	850
233	Application of Panel-Based Tests for Inherited Risk of Cancer. *Annual Review of Genomics and Human Genetics*, **2017**, 18, 201-227	9.7	23
232	Functional characterization of a multi-cancer risk locus on chr5p15.33 reveals regulation of TERT by ZNF148. *Nature Communications*, **2017**, 8, 15034	17.4	26
231	Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. *Clinical Cancer Research*, **2017**, 23, e68-e75	12.9	127
230	Recommendations for Cancer Surveillance in Individuals with RASopathies and Other Rare Genetic Conditions with Increased Cancer Risk. *Clinical Cancer Research*, **2017**, 23, e83-e90	12.9	77
229	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. *Npj Breast Cancer*, **2017**, 3, 22	7.8	78
228	Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. *Nature*, **2017**, 546, 431-435	50.4	544
227	A practical guide for evaluating gonadal germ cell tumor predisposition in differences of sex development. *American Journal of Medical Genetics, Part C: Seminars in Medical Genetics*, **2017**, 175, 304-314	3.1	29
226	Meta-analysis of five genome-wide association studies identifies multiple new loci associated with testicular germ cell tumor. *Nature Genetics*, **2017**, 49, 1141-1147	36.3	85
225	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
224	Characterizing Genetic Susceptibility to Breast Cancer in Women of African Ancestry. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1016-1026	4	12
223	Pheochromocytoma and Paraganglioma Susceptibility Genes: Estimating the Associated Risk of Disease. *JAMA Oncology*, **2017**, 3, 1212-1213	13.4	2
222	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
221	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. *Journal of Clinical Oncology*, **2017**, 35, 1262-1263	2.2	1
220	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
219	BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers. *Nature Communications*, **2017**, 8, 319	17.4	139

218	ALLELE-SPECIFIC COPY NUMBER ESTIMATION BY WHOLE EXOME SEQUENCING. *Annals of Applied Statistics*, **2017**, 11, 1169-1192	2.1	6
217	Association of breast cancer risk and the mTOR pathway in women of African ancestry in The RootQ Consortium. *Carcinogenesis*, **2017**, 38, 789-796	4.6	3
216	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. *Cell Reports*, **2017**, 21, 1936-1952	10.6	45
215	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. *Cell Reports*, **2017**, 21, 1953-1967	10.6	89
214	Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. *Clinical Cancer Research*, **2017**, 23, e107-e114	12.9	62
213	Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. *Clinical Cancer Research*, **2017**, 23, e123-e132	12.9	43
212	A functionally significant SNP in TP53 and breast cancer risk in African-American women. *Npj Breast Cancer*, **2017**, 3, 5	7.8	29
211	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
210	A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. *JCI Insight*, **2017**, 2, e89760	9.9	49
209	Discovery and fine-mapping of adiposity loci using high density imputation of genome-wide association studies in individuals of African ancestry: African Ancestry Anthropometry Genetics Consortium. *PLoS Genetics*, **2017**, 13, e1006719	6	60
208	Association of breast cancer risk in women of African ancestry with genetic variants in the TET-related DNA demethylation pathway.. *Journal of Clinical Oncology*, **2017**, 35, e13015-e13015	2.2	
207	Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma. *Clinical Cancer Research*, **2016**, 22, 374-82	12.9	28
206	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
205	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25
204	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
203	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
202	Counselling framework for moderate-penetrance cancer-susceptibility mutations. *Nature Reviews Clinical Oncology*, **2016**, 13, 581-8	19.4	200
201	Patient feedback and early outcome data with a novel tiered-binned model for multiplex breast cancer susceptibility testing. *Genetics in Medicine*, **2016**, 18, 25-33	8.1	44

200	Genomic Biomarkers for Breast Cancer Risk. *Advances in Experimental Medicine and Biology*, **2016**, 882, 1-32	3.6	26
199	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
198	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. *Clinical Cancer Research*, **2016**, 22, 1592-602	12.9	91
197	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	65
196	Muscle oxidative phosphorylation quantitation using creatine chemical exchange saturation transfer (CrCEST) MRI in mitochondrial disorders. *JCI Insight*, **2016**, 1, e88207	9.9	26
195	PIM kinases as therapeutic targets against advanced melanoma. *Oncotarget*, **2016**, 7, 54897-54912	3.3	14
194	Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma. *Oncotarget*, **2016**, 7, 71211-71222	3.3	9
193	Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. *Oncotarget*, **2016**, 7, 48577-48585	3.3	3
192	Cancer susceptibility mutations in individuals with breast and ovarian cancer using next-generation sequencing.. *Journal of Clinical Oncology*, **2016**, 34, 1515-1515	2.2	0
191	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
190	Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice. *PLoS ONE*, **2016**, 11, e0157125	3.7	7
189	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. *JAMA Oncology*, **2016**, 2, 1434-1440	13.4	151
188	Genetic variants in microRNA and microRNA biogenesis pathway genes and breast cancer risk among women of African ancestry. *Human Genetics*, **2016**, 135, 1145-59	6.3	24
187	Enhancing the evaluation of PI3K inhibitors through 3D´melanoma models. *Pigment Cell and Melanoma Research*, **2016**, 29, 317-28	4.5	11
186	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
185	Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors. *Clinical Genitourinary Cancer*, **2016**, 14, 524-529	3.3	1
184	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. *American Journal of Human Genetics*, **2016**, 98, 801-817	11	86
183	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58

182	Population Frequency of Germline BRCA1/2 Mutations. *Journal of Clinical Oncology*, **2016**, 34, 4183-4185	2.2	64
181	Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. *Human Molecular Genetics*, **2016**, 25, 4835-4846	5.6	34
180	Genetic changes associated with testicular cancer susceptibility. *Seminars in Oncology*, **2016**, 43, 575-581	5.5	21
179	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. *Journal of Clinical Oncology*, **2016**, 34, 4071-4078	2.2	110
178	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. *Cancer Discovery* , **2016**, 6, 1267-1275	24.4	30
177	Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. *Nature Communications*, **2015**, 6, 6140	17.4	115
176	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
175	Genomic Assessment of Renal Cancer **2015**, 39-56		
174	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
173	Association of HLA-DRB1 genetic variants with the persistence of atopic dermatitis. *Human Immunology*, **2015**, 76, 571-7	2.3	12
172	Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors. *Clinical Cancer Research*, **2015**, 21, 5215-21	12.9	13
171	Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. *Genetics in Medicine*, **2015**, 17, 630-8	8.1	101
170	Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. *Genetics in Medicine*, **2015**, 17, 485-92	8.1	60
169	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
168	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
167	MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. *Clinical Epigenetics*, **2015**, 7, 58	7.7	15
166	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
165	Gene-panel sequencing and the prediction of breast-cancer risk. *New England Journal of Medicine*, **2015**, 372, 2243-57	59.2	587

164	Rare inactivating PDE11A variants associated with testicular germ cell tumors. *Endocrine-Related Cancer*, **2015**, 22, 909-17	5.7	14
163	DCIS in BRCA1 and BRCA2 mutation carriers: prevalence, phenotype, and expression of oncodrivers C-MET and HER3. *Journal of Translational Medicine*, **2015**, 13, 335	8.5	12
162	Characteristics of high risk breast cancer patients with mutations identified by multiplex panel testing.. *Journal of Clinical Oncology*, **2015**, 33, 1511-1511	2.2	1
161	Impact of prior knowledge of mutation status on tumor stage in BRCA1/2 mutation carriers with newly diagnosed breast cancer.. *Journal of Clinical Oncology*, **2015**, 33, 1562-1562	2.2	1
160	Molecular Diagnostics and Tumor Mutational Analysis. *Cancer Drug Discovery and Development*, **2015**, 47-65	0.3	1
159	Interest in and outcomes with return of individual genetic research results for inherited susceptibility to breast cancer.. *Journal of Clinical Oncology*, **2015**, 33, e12503-e12503	2.2	
158	Oncotype DX scores in BRCA1 and BRCA2 associated breast cancer.. *Journal of Clinical Oncology*, **2015**, 33, 541-541	2.2	1
157	Two decades after BRCA: setting paradigms in personalized cancer care and prevention. *Science*, **2014**, 343, 1466-70	33.3	233
156	Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. *Clinical Cancer Research*, **2014**, 20, 5537-46	12.9	115
155	Panel testing for inherited susceptibility to breast, ovarian, and colorectal cancer. *Genetics in Medicine*, **2014**, 16, 827-9	8.1	9
154	A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. *Cancer Cell*, **2014**, 26, 344-357	24.3	303
153	Pathway-based analysis of GWAs data identifies association of sex determination genes with susceptibility to testicular germ cell tumors. *Human Molecular Genetics*, **2014**, 23, 6061-8	5.6	25
152	Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. *Clinical Cancer Research*, **2014**, 20, 3328-37	12.9	30
151	Hereditary kidney cancer syndromes. *Advances in Chronic Kidney Disease*, **2014**, 21, 81-90	4.7	93
150	Immune activation and a 9-year ongoing complete remission following CD40 antibody therapy and metastasectomy in a patient with metastatic melanoma. *Cancer Immunology Research*, **2014**, 2, 1051-8	12.5	32
149	Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2 activity. *Cancer Discovery*, **2014**, 4, 53-60	24.4	61
148	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Research* , **2014**, 16, 3419	8.3	82
147	Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. *Autophagy*, **2014**, 10, 1369-79	10.2	253

146	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
145	Prevalence of mutations in a panel of breast cancer susceptibility genes in patients with early onset breast cancer.. *Journal of Clinical Oncology*, **2014**, 32, 1510-1510	2.2	0
144	HIF inhibition in mRCC: Planned interim analysis of CRLX101 with bevacizumab (bev), a phase 1b/2a.. *Journal of Clinical Oncology*, **2014**, 32, e15611-e15611	2.2	1
143	Interim results of a phase 1b/2a study evaluating the nano pharmaceutical CRLX101 with bevacizumab (bev) in the treatment of patients (pts) with refractory metastatic renal cell carcinoma (mRCC).. *Journal of Clinical Oncology*, **2014**, 32, 412-412	2.2	2
142	A look back: Results from 1 year of routine clinical testing of both hematologic and solid tumors using two targeted next-generation sequencing (NGS) panels.. *Journal of Clinical Oncology*, **2014**, 32, e22099-e22099	2.2	
141	microRNA (miRNA) expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy (CP) in metastatic melanoma (MM) treated on the intergroup trial E2603.. *Journal of Clinical Oncology*, **2014**, 32, 9048-9048	2.2	
140	Germ-line DICER1 mutations do not make a major contribution to the etiology of familial testicular germ cell tumours. *BMC Research Notes*, **2013**, 6, 127	2.3	12
139	Cutaneous Hamartoneoplastic Disorders **2013**, 1-13		
138	Immunotherapy at large: the road to personalized cancer vaccines. *Nature Medicine*, **2013**, 19, 1098-100	50.5	41
137	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. *Nature Genetics*, **2013**, 45, 1226-1231	36.3	205
136	Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. *Human Molecular Genetics*, **2013**, 22, 2748-53	5.6	53
135	A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. *Cancer Research*, **2013**, 73, 265-75	10.1	77
134	The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. *Clinical Cancer Research*, **2013**, 19, 1784-94	12.9	74
133	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
132	The molecular biology of renal cell carcinoma. *Seminars in Oncology*, **2013**, 40, 421-8	5.5	39
131	Common breast cancer risk variants in the post-COGS era: a comprehensive review. *Breast Cancer Research*, **2013**, 15, 212	8.3	41
130	A genome-wide association study of breast cancer in women of African ancestry. *Human Genetics*, **2013**, 132, 39-48	6.3	63
129	Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. *Cell Reports*, **2013**, 4, 1090-9	10.6	141

128	Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. *Annals of Surgical Oncology*, **2013**, 20, 1444-50	3.1	153
127	Meta-analysis identifies four new loci associated with testicular germ cell tumor. *Nature Genetics*, **2013**, 45, 680-5	36.3	132
126	A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. *Nature Genetics*, **2013**, 45, 690-6	36.3	192
125	Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. *Carcinogenesis*, **2013**, 34, 1520-8	4.6	24
124	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
123	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
122	Comparison of address-based sampling and random-digit dialing methods for recruiting young men as controls in a case-control study of testicular cancer susceptibility. *American Journal of Epidemiology*, **2013**, 178, 1638-47	3.8	23
121	Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). *Clinical Cancer Research*, **2013**, 19, 4868-78	12.9	145
120	Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. *Cancer Discovery* , **2013**, 3, 399-405	24.4	106
119	Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. *Cancer*, **2013**, 119, 1344-8	6.4	37
118	Retrospective, correlative study of BRAF mutation V600E in testicular cancer patients.. *Journal of Clinical Oncology*, **2013**, 31, e15584-e15584	2.2	1
117	The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. *PLoS ONE*, **2013**, 8, e59588	3.7	48
116	Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. *PLoS ONE*, **2013**, 8, e69748	3.7	2
115	NRAS and BRAF mutations in atypical melanocytic lesions arising in melanoma patients treated with vemurafenib.. *Journal of Clinical Oncology*, **2013**, 31, 9017-9017	2.2	
114	The mutational spectrum of breast and ovarian tumors from BRCA1 and BRCA2 mutation carriers.. *Journal of Clinical Oncology*, **2013**, 31, 1510-1510	2.2	
113	ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. *Human Mutation*, **2012**, 33, 2-7	4.7	211
112	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
111	Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. *Breast Cancer Research and Treatment*, **2012**, 132, 341-5	4.4	12

110	Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 136, 295-302	4.4	3
109	Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. *Cancer Genetics*, **2012**, 205, 1-11	2.3	142
108	Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. *PLoS ONE*, **2012**, 7, e35706	3.7	10
107	Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. *Carcinogenesis*, **2012**, 33, 835-40	4.6	59
106	Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. *Cancer Research*, **2012**, 72, 112-21	10.1	51
105	The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2012**, 132, 1119-26	4.4	7
104	Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF). *Frontiers in Endocrinology*, **2012**, 3, 163	5.7	12
103	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1362-70	4	20
102	Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 552-6	4	10
101	Molecular testing in melanoma. *Cancer Journal (Sudbury, Mass)*, **2012**, 18, 117-23	2.2	17
100	Hybrid peripheral nerve sheath tumor. *Journal of Neurosurgery*, **2012**, 117, 897-901	3.2	13
99	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
98	Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. *Cancer Research*, **2011**, 71, 5792-805	10.1	44
97	Therapeutic approaches for women predisposed to breast cancer. *Annual Review of Medicine*, **2011**, 62, 295-306	17.4	28
96	Exploring the link between MORF4L1 and risk of breast cancer. *Breast Cancer Research*, **2011**, 13, R40	8.3	16
95	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
94	PALB2 mutations in familial breast and pancreatic cancer. *Familial Cancer*, **2011**, 10, 225-31	3	82
93	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. *Human Genetics*, **2011**, 130, 685-99	6.3	15

92	Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dub syndrome. *Genes Chromosomes and Cancer*, **2011**, 50, 466-77	5	44
91	Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. *Genes Chromosomes and Cancer*, **2011**, 50, 606-18	5	72
90	PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. *Cancer Research*, **2011**, 71, 2750-60	10.1	419
89	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 3304-21	5.6	62
88	Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1690-702	4	16
87	The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. *Clinical Cancer Research*, **2011**, 17, 3742-50	12.9	45
86	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 4732-47	5.6	21
85	A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. *Human Molecular Genetics*, **2011**, 20, 3109-17	5.6	114
84	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
83	Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin lymphoma. *Nature Medicine*, **2011**, 17, 941-3	50.5	128
82	Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. *PLoS Biology*, **2011**, 9, e1001199	9.7	73
81	Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. *Clinical Cancer Research*, **2011**, 17, 3478-89	12.9	184
80	Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. *Nature*, **2010**, 467, 596-9	50.4	1379
79	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
78	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2010**, 19, 2886-97	5.6	56
77	Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2859-68	4	32
76	Biallelic TSC gene inactivation in tuberous sclerosis complex. *Neurology*, **2010**, 74, 1716-23	6.5	116
75	Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. *PLoS Genetics*, **2010**, 6, e1001183	6	74

74	Diagnosis of adult hereditary pulmonary disease and the role of genetic testing. *Chest*, **2010**, 137, 976-82	5.3	4
73	Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. *Genes and Cancer*, **2010**, 1, 152-163	2.9	230
72	Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2010**, 12, R102	8.3	21
71	Predisposition alleles for Testicular Germ Cell Tumour. *Current Opinion in Genetics and Development* , **2010**, 20, 225-30	4.9	20
70	The International Testicular Cancer Linkage Consortium: a clinicopathologic descriptive analysis of 461 familial malignant testicular germ cell tumor kindred. *Urologic Oncology: Seminars and Original Investigations*, **2010**, 28, 492-9	2.8	35
69	Distinct MHC gene expression patterns during progression of melanoma. *Genes Chromosomes and Cancer*, **2010**, 49, 144-54	5	21
68	Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. *Biochemical Pharmacology*, **2010**, 80, 755-61	6	28
67	Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. *Cancer Cell*, **2010**, 18, 683-95	24.3	1007
66	Molecular Genetics of Testicular Germ Cell Tumor **2010**, 181-199		
65	HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 14391-6	11.5	156
64	Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. *Cancer Research*, **2009**, 69, 3241-4	10.1	60
63	Active Notch1 confers a transformed phenotype to primary human melanocytes. *Cancer Research*, **2009**, 69, 5312-20	10.1	93
62	Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. *Cancer Research*, **2009**, 69, 5801-10	10.1	27
61	Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. *Cancer Research*, **2009**, 69, 7030-7	10.1	15
60	Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases. *Clinical Cancer Research*, **2009**, 15, 7711-7718	12.9	95
59	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
58	Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. *Clinical Cancer Research*, **2009**, 15, 1076-85	12.9	35
57	Malignant paraganglioma associated with succinate dehydrogenase subunit B in an 8-year-old child: the age of first screening?. *Pediatric Nephrology*, **2009**, 24, 1239-42	3.2	14

56	Deletion of 15q11.2-15q13.1 in isolated human hemimegalencephaly. *Acta Neuropathologica*, **2009**, 118, 821-3	14.3	4
55	No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research and Treatment*, **2009**, 115, 307-13	4.4	9
54	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. *Breast Cancer Research and Treatment*, **2009**, 117, 371-9	4.4	10
53	Younger age-at-diagnosis for familial malignant testicular germ cell tumor. *Familial Cancer*, **2009**, 8, 451-6		16
52	Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. *Nature Genetics*, **2009**, 41, 811-5	36.3	294
51	Comprehensive characterization of the DNA amplification at 13q34 in human breast cancer reveals TFDP1 and CUL4A as likely candidate target genes. *Breast Cancer Research*, **2009**, 11, R86	8.3	68
50	Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. *Breast Cancer Research*, **2009**, 11, R76	8.3	41
49	Other Hereditary Breast Cancer Syndromes and Genes **2009**, 131-162		
48	HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. *Cancer Cell*, **2008**, 14, 435-46	24.3	384
47	The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families. *Cancer Research*, **2008**, 68, 7006-14	10.1	92
46	The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. *Clinical Cancer Research*, **2008**, 14, 230-9	12.9	197
45	Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutations. *Genetic Testing and Molecular Biomarkers*, **2008**, 12, 81-91		107
44	Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas. *Molecular Cancer Therapeutics*, **2008**, 7, 2876-83	6.1	246
43	Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. *Cancer Research*, **2008**, 68, 5743-52	10.1	79
42	Analysis of the DND1 gene in men with sporadic and familial testicular germ cell tumors. *Genes Chromosomes and Cancer*, **2008**, 47, 247-52	5	31
41	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *American Journal of Human Genetics*, **2008**, 82, 937-48	11	218
40	Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. *Journal of Molecular Diagnostics*, **2007**, 9, 464-71	5.1	91
39	Network modeling links breast cancer susceptibility and centrosome dysfunction. *Nature Genetics*, **2007**, 39, 1338-49	36.3	516

38	Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. *Clinical Breast Cancer*, **2007**, 7, 627-33	3	6
37	Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. *Cancer Research*, **2007**, 67, 3594-600	10.1	58
36	AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 1416-21	4	26
35	Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. *Cancer Research*, **2007**, 67, 1494-501	10.1	98
34	Estrogen receptor status could modulate the genomic pattern in familial and sporadic breast cancer. *Clinical Cancer Research*, **2007**, 13, 7305-13	12.9	28
33	A comparison of DNA copy number profiling platforms. *Cancer Research*, **2007**, 67, 10173-80	10.1	58
32	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *American Journal of Human Genetics*, **2007**, 81, 1186-200	11	204
31	A genome wide linkage search for breast cancer susceptibility genes. *Genes Chromosomes and Cancer*, **2006**, 45, 646-55	5	100
30	The von Hippel-Lindau (VHL) germline mutation V84L manifests as early-onset bilateral pheochromocytoma. *American Journal of Medical Genetics, Part A*, **2006**, 140, 685-90	2.5	18
29	Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic. *Cancer Biology and Therapy*, **2006**, 5, 1098-102	4.6	23
28	Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. *Human Molecular Genetics*, **2006**, 15, 443-51	5.6	127
27	A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 2542-5	4	44
26	The tuberous sclerosis complex. *New England Journal of Medicine*, **2006**, 355, 1345-56	59.2	1328
25	Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. *Pigment Cell & Melanoma Research*, **2006**, 19, 290-302		378
24	The Y deletion gr/gr and susceptibility to testicular germ cell tumor. *American Journal of Human Genetics*, **2005**, 77, 1034-43	11	172
23	Adjusting the estimated proportion of breast cancer cases associated with BRCA1 and BRCA2 mutations: public health implications. *Genetics in Medicine*, **2005**, 7, 28-33	8.1	58
22	An evaluation of BRCA1 and BRCA2 founder mutations penetrance estimates for breast cancer among Ashkenazi Jewish women. *Genetics in Medicine*, **2005**, 7, 34-9	8.1	13
21	Inherited susceptibility for pediatric cancer. *Cancer Journal (Sudbury, Mass)*, **2005**, 11, 255-67	2.2	17

20	Resolving ATM haplotypes in whites. *American Journal of Human Genetics*, **2003**, 72, 1071-3	11	1
19	Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. *American Journal of Human Genetics*, **2003**, 72, 1023-8	11	104
18	Pheochromocytoma: the expanding genetic differential diagnosis. *Journal of the National Cancer Institute*, **2003**, 95, 1196-204	9.7	199
17	BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. *Journal of Clinical Oncology*, **2002**, 20, 994-9	2.2	61
16	Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. *Nature Genetics*, **2002**, 31, 55-9	36.3	863
15	Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. *Journal of the National Cancer Institute*, **2002**, 94, 1365-72	9.7	498
14	Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 827-31	11.5	64
13	CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q. *Human Molecular Genetics*, **2002**, 11, 1327-32	5.6	25
12	Absence of evidence for a familial breast cancer susceptibility gene at chromosome 8p12-p22. *Oncogene*, **2000**, 19, 4170-3	9.2	32
11	Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. *American Journal of Human Genetics*, **2000**, 67, 841-50	11	136
10	Association of HPC2/ELAC2 genotypes and prostate cancer. *American Journal of Human Genetics*, **2000**, 67, 1014-9	11	121
9	Successful use of alternate waste nitrogen agents and hemodialysis in a patient with hyperammonemic coma after heart-lung transplantation. *Archives of Neurology*, **1999**, 56, 481-4		35
8	Multiple vascular and bowel ruptures in an adolescent male with sporadic Ehlers-Danlos syndrome type IV. *Pediatric and Developmental Pathology*, **1999**, 2, 86-93	2.2	22
7	I1307K APC variant in non-Ashkenazi Jewish women affected with breast cancer **1999**, 85, 189-190		5
6	The APCI1307K allele and breast cancer risk. *Nature Genetics*, **1998**, 20, 13-4	36.3	59
5	Intestinal perforation in Ehlers-Danlos syndrome after enema treatment for constipation. *Journal of Pediatric Gastroenterology and Nutrition*, **1998**, 27, 599-602	2.8	13
4	Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk		1
3	Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes		2

List of Publications

2	Assessment of Polygenic Architecture and Risk Prediction based on Common Variants Across Fourteen Cancers	1
1	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses	2